ReviewBiomedicines2026
Chemotherapy-Induced Neurotoxicity: Molecular Mechanisms, Biomarkers and Emerging Neuroprotective Strategies.
Review in Biomedicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemotherapy-induced neurotoxicity is a major dose-limiting complication of systemic anticancer therapy that adversely affects neurological function, treatment continuity, and long-term quality of life among cancer survivors. Chemotherapy-induced peripheral neuropathy (CIPN) is the most common manifestation, whereas chemotherapy-related cognitive impairment (CRCI) and selected immune-mediated neurological toxicities increasingly contribute to survivorship-related morbidity. Although these immune-mediated syndromes are distinct from conventional chemotherapy-induced neurotoxicity, they are included because they share several downstream pathogenic mechanisms relevant to biomarker discovery and neuroprotective strategies. This structured narrative review critically synthesizes current evidence on the molecular mechanisms, clinical manifestations, biomarkers, and emerging neuroprotective strategies underlying chemotherapy-induced neurotoxicity. A comprehensive PubMed/MEDLINE search was performed, with emphasis on studies published between 2014 and 2026. Evidence from systematic reviews, meta-analyses, clinical guidelines, randomized controlled trials, prospective clinical studies, and high-quality translational research was critically evaluated. Current evidence indicates that chemotherapy-induced neurotoxicity arises through interconnected mechanisms involving oxidative stress, mitochondrial dysfunction, neuroinflammation, calcium dysregulation, blood-brain barrier disruption, and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.